Journal of Clinical Oncology, Vol 16, 2052-2059, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

V Leblond, F Davi, F Charlotte, R Dorent, MO Bitker, L Sutton, I Gandjbakhch, JL Binet and M Raphael
Departement d'Hematologie, Hopital Pitie-Salpetriere, Paris, France. veronique.leblond@psl.ap-hp-paris.fr

PURPOSE: Organ recipients are at a high risk of posttransplant lymphoproliferative disorders (PTLD) as a result of immunosuppressive therapy. Most B-cell lymphomas are associated with Epstein-Barr virus (EBV) infection. We describe a morphologically and clinically distinct group of PTLD in 11 patients that occurred late after organ transplantation and were not associated with EBV. PATIENTS AND METHODS: There were seven kidney, three heart, and one liver transplant recipients (group I). The clinical manifestations, pathologic findings, treatment, and outcome were compared with those in 21 patients with EBV- associated PTLD treated in our institution (group II). EBV was detected with at least two techniques: Epstein-Barr-encoded RNA (EBER) in situ hybridization with EBER 1 + 2 probes, Southern blotting, and detection of latent membrane protein 1 (LMP1) expression by immunohistochemistry. RESULTS: The time between transplantation and the diagnosis of lymphoma ranged from 180 to 10,220 days in group I (mean, 2,234; median, 1,800) and from 60 to 2,100 days in group II (mean, 546; median, 180), and was significantly shorter in group II (P = .02). Among 19 tumors diagnosed within 2 years after the graft, 16 were associated with EBV; among 13 tumors diagnosed after more than 2 years, only five were associated with EBV. All of the B-cell PTLDs in group I were classified as monomorphic, meeting the criteria of B diffuse large-cell lymphoma (B- DLCL) with a component of immunoblasts, and genotyping confirmed their monoclonality. Three tumors were T-cell pleomorphic lymphomas. Tumor sites were mainly bone marrow and lymph nodes. Overall median survival was 1 month in group I and 37 months in group II, with two patients still alive in group I and nine in group II. The survival time was significantly longer in group II (P < .01). CONCLUSION: EBV-negative PTLD may be a late serious complication of organ transplantation. Half the tumors observed after kidney transplantation in our center were not associated with EBV and emerged after more than 5 years, which suggests the number of EBV-negative PTLDs in organ recipients might increase with time.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. T. van Leeuwen, A. E. Grulich, A. C. Webster, M. R.E. McCredie, J. H. Stewart, S. P. McDonald, J. Amin, J. M. Kaldor, J. R. Chapman, and C. M. Vajdic Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation Blood, July 16, 2009; 114(3): 630 - 637. [Abstract] [Full Text] [PDF]

				J. S. Knight, A. Tsodikov, D. M. Cibrik, C. W. Ross, M. S. Kaminski, and D. W. Blayney Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center J. Clin. Oncol., July 10, 2009; 27(20): 3354 - 3362. [Abstract] [Full Text] [PDF]

				M. J Everly, R. D Bloom, D. E Tsai, and J. Trofe Posttransplant Lymphoproliferative Disorder Ann. Pharmacother., November 1, 2007; 41(11): 1850 - 1858. [Abstract] [Full Text] [PDF]

				H. Williams and D. H. Crawford Epstein-Barr virus: the impact of scientific advances on clinical practice Blood, February 1, 2006; 107(3): 862 - 869. [Abstract] [Full Text] [PDF]

				I. M. Ghobrial, T. M. Habermann, M. J. Maurer, S. M. Geyer, K. M. Ristow, T. S. Larson, R. C. Walker, S. M. Ansell, W. R. Macon, G. G. Gores, et al. Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders J. Clin. Oncol., October 20, 2005; 23(30): 7574 - 7582. [Abstract] [Full Text] [PDF]

				T. G. Gross, J. C. Bucuvalas, J. R. Park, T. C. Greiner, S. H. Hinrich, S. S. Kaufman, A. N. Langnas, R. A. McDonald, F. C. Ryckman, B. W. Shaw, et al. Low-Dose Chemotherapy for Epstein-Barr Virus-Positive Post-Transplantation Lymphoproliferative Disease in Children After Solid Organ Transplantation J. Clin. Oncol., September 20, 2005; 23(27): 6481 - 6488. [Abstract] [Full Text] [PDF]

				C. N. Kotton and J. A. Fishman Viral Infection in the Renal Transplant Recipient J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1758 - 1774. [Abstract] [Full Text] [PDF]

				M. E. Halkos, J. I. Miller, K. P. Mann, D. L. Miller, and A. A. Gal Thoracic Presentations of Posttransplant Lymphoproliferative Disorders Chest, December 1, 2004; 126(6): 2013 - 2020. [Abstract] [Full Text] [PDF]

				D. Capello, M. Cerri, G. Muti, E. Berra, P. Oreste, C. Deambrogi, D. Rossi, G. Dotti, A. Conconi, M. Vigano, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders Blood, November 15, 2003; 102(10): 3775 - 3785. [Abstract] [Full Text] [PDF]

				Y Sadahira, K Kumori, Y Mikami, T Otsuki, T Manabe, and K Aoyama Post-transplant malignant lymphoma with monoclonal immunoglobulin gene rearrangement and polyclonal Epstein-Barr virus episomes J. Clin. Pathol., November 1, 2001; 54(11): 887 - 889. [Abstract] [Full Text] [PDF]

				I. Molnar and Y.-K. Keung Treatment of post-transplant lymphoproliferative disorder with rituximab and radiation in a patient with second renal allograft Nephrol. Dial. Transplant., October 1, 2001; 16(10): 2114 - 2115. [Full Text] [PDF]

				C. L. Moertel, B. Carlson-Green, J. Watterson, and S. C. Simonton Lymphomatoid Granulomatosis After Childhood Acute Lymphoblastic Leukemia: Report of Effective Therapy Pediatrics, May 1, 2001; 107(5): 82e - 82. [Abstract] [Full Text]

				M. L. Gulley Molecular Diagnosis of Epstein-Barr Virus-Related Diseases J. Mol. Diagn., February 1, 2001; 3(1): 1 - 10. [Abstract] [Full Text]

				M-F. Mamzer-Bruneel, C. Lome, E. Morelon, V. Levy, P. Bourquelot, F. Jacobs, A. Gessain, E. Mac Intyre, N. Brousse, H. Kreis, et al. Durable Remission After Aggressive Chemotherapy for Very Late Post-Kidney Transplant Lymphoproliferation: A Report of 16 Cases Observed in a Single Center J. Clin. Oncol., November 1, 2000; 18(21): 3622 - 3632. [Abstract] [Full Text] [PDF]

				P. B. Sagireddy, P. E. Pergola, D. J. Riley, D. H. Boldt, and B. S. Kasinath Non-clonal large granular cell lymphocytosis after renal transplantation Nephrol. Dial. Transplant., September 1, 2000; 15(9): 1485 - 1486. [Full Text] [PDF]

				A. Martin, F. Baran-Marzak, S. El Mansouri, C. Legendre, V. Leblond, F. Charlotte, F. Davi, D. Canioni, and M. Raphael Expression of p16/INK4a in Posttransplantation Lymphoproliferative Disorders Am. J. Pathol., May 1, 2000; 156(5): 1573 - 1579. [Abstract] [Full Text] [PDF]

				T. Greiner, J. O. Armitage, and T. G. Gross Atypical Lymphoproliferative Diseases Hematology, January 1, 2000; 2000(1): 133 - 146. [Abstract] [Full Text] [PDF]

				R. E. Curtis, L. B. Travis, P. A. Rowlings, G. Socie, D. W. Kingma, P. M. Banks, E. S. Jaffe, G. E. Sale, M. M. Horowitz, R. P. Witherspoon, et al. Risk of Lymphoproliferative Disorders After Bone Marrow Transplantation: A Multi-Institutional Study Blood, October 1, 1999; 94(7): 2208 - 2216. [Abstract] [Full Text] [PDF]